Skip to main content
. 2009 Aug 20;28(1):118. doi: 10.1186/1756-9966-28-118

Figure 5.

Figure 5

Overall survival depending on the immunopanel ('Vimentin or CK5/6 or 14 or 17') used in the determination of basal type tumours. Patients with triple negative cancer (n = 54).